Recent trials have explored the efficacy of PD-1 and CTLA-4 targeted immunotherapies in osteosarcoma (Wang et al., 2016; Ratti et al., 2017; Hennessy et al., 2021). The gene discussed is PDCD1; the disease is osteosarcoma.